Geron (GERN) Rockets 50% After Stem Cell Trial Cleared By FDA

Geron Corporation (Nasdaq: GERN) is continuing to rocket higher following news this morning that the FDA has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. Geron said this is the world's first human clinical trial of embryonic stem cell-based therapy. The stock is now up 50%.

Geron competitors are also higher on the news: Aastrom Biosciences, Inc. (Nasdaq: ASTM) is up 30% and StemCells Inc. (Nasdaq: STEM) is up 30%.

You May Also Be Interested In

• BofA Securities on Abbott Labs (ABT): 'durable revenue growth at the high end of medtech and double-digit EPS growth'
• Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'highly unlikely that this appeal changes much'
• Piper Sandler Defending Methanex (MEOH)